Related Experiment Video
Updated: Jan 10, 2026
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
Multistrain probiotics alleviate gastrointestinal symptoms during bismuth quadruple therapy for Helicobacter pylori
Wen-Jun Liu1, Yue-Ming Zhao2, Qing-Qing Xie1
1Department of Nutrition Science and Food Hygiene, Xiangya School of Public Health, Central South University, Changsha 410078, Hunan Province, China.
Background:
Bismuth quadruple therapy (BQT) induces troublesome gastrointestinal side effects that reduce adherence and efficacy.
Aim:
To evaluate multistrain probiotics efficacy for alleviating gastrointestinal symptoms during BQT for Helicobacter pylori (H. pylori) eradication.
Methods:
One hundred seventy-four adults (18-60 years) with confirmed H. pylori infections between July 2022 and December 2023 were randomised to receive BQT plus a multispecies probiotic (n = 89) or a maltodextrin placebo (n = 85) for 4 weeks. Gastrointestinal Symptom Rating Scale (GSRS) and Bristol Stool Classification Scale scores were collected at baseline, 2, 4 and 8 weeks; eradication was assessed 8 weeks post-treatment. Intention-to-treat analysis used multiple imputation and SPSS 26.0.
Results:
After 8 weeks, GSRS scores (all dimensions and total) decreased significantly compared with those at baseline. ITT analysis showed significantly greater reductions for the intervention vs the placebo in reflux by week 2, total/diarrhea scores by week 4, and total/dyspepsia scores by week 8. Probiotics provided no protective effect against gastrointestinal symptoms at week 2 but showed significant protection at weeks 4 and 8. Both groups reported decreased diarrhea/constipation-type stools and increased normal-type stools post-intervention. H. pylori eradication rates were slightly higher for the intervention group (88.8%) than for the placebo group (84.7%), but the difference was not significant (P = 0.430).
Conclusion:
Multistrain probiotics significantly relieved BQT-associated gastrointestinal symptoms without affecting eradication success.
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:21Drugs for Treatment of Constipation-Predominant IBS
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors